Khondrion completes enrollment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders
Khondrion today announced that the last patient has been dosed with sonlicromanol in the KHENERGYZE Phase IIb clinical study.